65662-66-0

Upstream product

• 5471-96-5 1,3-bis(4-bromophenyl)-2-propen-1-one 
• 29881-14-9 1,2-diphenyl-cyclopropane 
• 103-30-0 (E)-1,2-diphenyl-ethene 
• 1122-91-4 4-bromo-benzaldehyde 
• 2039-82-9 1-bromo-4-ethenyl-benzene 
• 99-90-1 para-bromoacetophenone 
• 494764-44-2 3,5-Bis-(4-bromo-phenyl)-4,5-dihydro-1H-pyrazole 
• 1138-48-3 cis-1,2-diphenylcyclopropane 

Downstream Products

• 1250938-61-4 trans-1,2-Di-(p-bromphenyl)-cyclopropan 
• 1250935-57-9 (1S,2S)-1,2-bis(4-bromophenyl)cyclopropane 
• 1422040-83-2 C₄₁H₄₂N₄O₄ 
• 1422041-07-3 C₁₅H₁₆N₂ 

Relevant academic research and scientific papers

Iron-catalyzed synthesis of cyclopropanes by in situ generation and decomposition of electronically diversified diazo compounds

The modular synthesis of a variety of trans 1,2-disubstituted cyclopropanes in a safe and user-friendly one-pot iron-catalyzed cyclopropanation reaction is described. Easily synthesized N-nosylhydrazones are used as diazo precursors, allowing the in situ generation of electron-rich diazo compounds under mild reaction conditions and their direct participation in the cyclopropanation reaction.

HCV NS5A replication complex inhibitors. Part 3

In a recent disclosure,1 we described the discovery of dimeric, prolinamide-based NS5A replication complex inhibitors exhibiting excellent potency towards an HCV genotype 1b replicon. That disclosure dealt with the SAR exploration of the peripheral region of our lead chemotype, and herein is described the SAR uncovered from a complementary effort that focused on the central core region. From this effort, the contribution of the core region to the overall topology of the pharmacophore, primarily vector orientation and planarity, was determined, with a set of analogs exhibiting 50 in a genotype 1b replicon assay.

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds

HEPATITIS C VIRUS INHIBITORS

This disclosure concerns novel compounds of Formula (I) as defined in the specification and compositions comprising such novel compounds. These compounds are useful antiviral agents, especially in inhibiting the function of the NS5A protein encoded by Hepatitis C virus (HCV). Thus, the disclosure also concerns a method of treating HCV related diseases or conditions by use of these novel compounds or a composition comprising such novel compounds.

Kinetic Study of the Homolytic Brominolysis of 1,2-Diarylcyclopropanes

The rate constants for the photolytic brominolysis of 22 trans-1,2-diarylcyclopropanes in carbon disulfide relative to an internal standard, p-chlorotoluene, have been determined.The products of the brominolysis are 1,3-dibromo-1,3-diarylpropanes.The rate constants range over 5 orders of magnitude, being enhanced by electrondonating substituents on one or both benzene rings.The quantitative size of the substituent effect (ρ) at either involved carbon center is a function of the substituent at the other center.This fact suggests a continuum of transition-state structures with varying degrees of bond breaking and charge separation.